Drawing for MUNA MEDICAL UTILITY NETWORK ACCREDITOR

USPTO serial 90029109

MUNA MEDICAL UTILITY NETWORK ACCREDITOR

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
HELMERS, SARA A
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MUNA MEDICAL UTILITY NETWORK ACCREDITOR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael G Shariff

Michael G Shariff INVENTA CAPITAL PLC40900 WOODWARD AVENUE SUITE 111BLOOMFIELD HILLS, MI 48304United States

Goods and services

ClassDescriptionStatusFirst use
009Downloadable software application for tracking, managing, and analyzing data for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases; downloadable computer programs for tracking, managing, and analyzing data for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases; downloadable software in the nature of a mobile application for tracking, managing, and analyzing data for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases; downloadable software application for smartphones and tablet computers that allows users to receive data over a wireless communication network from a Polymerase Chain Reaction (PCR) testing system, save them and represent them in graphical format; downloadable software application for sending data and GPS coordinates via blockchain to a dedicated storage location in order to inform authorities about the presence of the infectious disease, and also for connecting with a Polymerase Chain Reaction (PCR) testing system in order to download testing data, plot the data, and/or automatically send the data via LTE network to a dedicated storage location for the purposes of monitoring the disease outbreak; electronic communications device for automatically uploading information over a wireless communication network to a smartphone and then wirelessly sending the information to a secure blockchain powered global network, instantly making the test results available anywhere in the worldACTIVE—
010Medical device and apparatus for use in the testing and diagnosis of COVID-19, coronavirus, and viruses; medical testing and diagnostic device and apparatus for the detection of COVID-19, coronavirus, and viruses; computerized medical recording and analysis apparatus for the diagnosis of COVID-19, coronavirus, and viruses; medical device and apparatus for use in the testing and diagnosis of COVID-19, coronavirus, and viruses, which also automatically uploads the testing information over a wireless communication network to a smartphone and then wirelessly sends the information to a secure blockchain powered global network, instantly making the test results available anywhere in the worldACTIVE—
042Providing online non-downloadable software to track, manage, and analyze data related to employee, customer and passenger health status; platform as a services (PaaS) featuring software for rapidly reviewing and analyzing COVID-19 test results, and communicating those results; scientific research consulting services in the field of immunology; scientific research consulting services in the field of antibodies for use in targeting the CCR5 cell receptor; scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor; medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the foregoing excluding medical research and scientific research consulting services directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting; medical and scientific research in the field of testing and diagnosis of COVID-19, coronavirus, and other diseases; software as a service (SAAS) services featuring software for tracking, managing, and analyzing data for use in the testing and diagnosis of COVID-19, coronavirus, and other diseasesACTIVE—
044Healthcare, wellness and medical services; medical services, namely, provision of clinical assessments, evaluations and diagnostic lab testing; providing healthcare, wellness information and public health information in connection with infectious disease and COVID-19; Medical testing for diagnostic or treatment purposes, namely, on-site testing for diagnosis and treatment of COVID-19, including both testing and analysis of test results; providing a website featuring medical information; providing a website featuring information in the field of antibodies for use in targeting the CCR5 cell receptor; providing health and medical information, namely, providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the forgoing excluding information directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting; medical analysis services for diagnostic purposes; providing information relating to the testing and diagnosis of COVID-19, coronavirus, and other diseases; providing a website featuring news and information relating to the testing and diagnosis of COVID-19, coronavirus, and other diseases; charitable services, namely, providing medical devices and services for use in the testing and diagnosis of COVID-19, coronavirus, and other diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 16, 2024MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 16, 2024ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 13, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 12, 2024EX4GSOU EXTENSION 4 GRANTED—
Feb 12, 2024EXT4SOU EXTENSION 4 FILED—
Feb 12, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 16, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 14, 2023EX3GSOU EXTENSION 3 GRANTED—
Aug 14, 2023EXT3SOU EXTENSION 3 FILED—
Aug 14, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 17, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 15, 2023EX2GSOU EXTENSION 2 GRANTED—
Feb 15, 2023EXT2SOU EXTENSION 2 FILED—
Feb 15, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 17, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 15, 2022EX1GSOU EXTENSION 1 GRANTED—
Aug 15, 2022EXT1SOU EXTENSION 1 FILED—
Aug 15, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 15, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 21, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 21, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 1, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 18, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 18, 2021XAECEXAMINER'S AMENDMENT ENTERED—
Nov 18, 2021GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 18, 2021GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 18, 2021CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 17, 2021ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Sep 14, 2021PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Aug 27, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 10, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 10, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 10, 2021ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Aug 9, 2021GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Aug 9, 2021GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 9, 2021CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 5, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 5, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 5, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 5, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 5, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 5, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 22, 2021DOCKASSIGNED TO EXAMINER—
Jul 23, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 3, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance